Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus dexamethasone with maintenance for relapsed multiple myeloma
ACTRN12606000180516Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Overall response. Started Jun 2006; status: completed.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12606000180516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000180516.